Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Springer Nature
Abstract
CD19-targeted chimeric antigen receptor (CAR) T cell therapy has shown high efficacy in patients with refractory B-cell malignancies such as non-Hodgkin lymphoma and acute lymphoblastic leukemia. Despite promising results, responses are not durable in most patients. In addition, patients receiving CD19 CAR T cell therapy are at risk of developing severe, potentially life-threatening, adverse events including cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome. Many combinatorial approaches are currently being investigated to improve CAR T cell in vivo function, antitumor effects, and mitigate toxicities. In this review, we discuss the use of ibrutinib and immune checkpoint inhibitors in combination with CAR T cell therapy in patients with lymphoid B-cell malignancies. © 2021, The Author(s), under exclusive licence to Springer Nature Limited.
Description
Keywords
Antigens, cd19, Humans, Immune checkpoint inhibitors, Immunotherapy, adoptive, Precursor cell lymphoblastic leukemia-lymphoma, Protein kinase inhibitors, Receptors, antigen, t-cell, Receptors, chimeric antigen, T-lymphocytes, Axicabtagene ciloleucel, Bruton tyrosine kinase inhibitor, Durvalumab, Ibrutinib, Immune checkpoint inhibitor, Pembrolizumab, Tisagenlecleucel t, Cd19 antigen, Lymphocyte antigen receptor, Protein kinase inhibitor, Acute lymphoblastic leukemia, Antineoplastic activity, Cell activation, Cell function, Cell proliferation, Chimeric antigen receptor t-cell immunotherapy, Chronic lymphatic leukemia, Clinical effectiveness, Diffuse large b cell lymphoma, Disease severity, Drug efficacy, Drug use, Human, Large cell lymphoma, Nonhodgkin lymphoma, Nonhuman, Review, Treatment failure, Treatment response, Tumor growth, Adoptive immunotherapy, Procedures, T lymphocyte